Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B
A recent consensus document has defined metabolic dysfunction-associated fatty liver disease (MAFLD) as hepatic steatosis together with overweight, diabetes, and/or a combination of other metabolic risk factors. The clinical relevance of this novel diagnosis is unknown among patients with chronic he...
Сохранить в:
| Главные авторы: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | английский |
| Опубликовано: |
2021
|
| Online-ссылка: | https://doi.org/10.1016/j.jhepr.2021.100350 http://www.jhep-reports.eu/article/S2589555921001269/pdf |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|